{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:16:40Z","timestamp":1788553000448,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.04.045","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:57:05Z","timestamp":1778767025000},"page":"1053.e1-1053.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Disorders: An Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-5738","authenticated-orcid":false,"given":"Leslie","family":"Crofford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Jallouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-9796","authenticated-orcid":false,"given":"Daniel W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Piquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-5252","authenticated-orcid":false,"given":"Shaun W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8179-5789","authenticated-orcid":false,"given":"Alejandro Marinos","family":"Velarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan E.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-1979","authenticated-orcid":false,"given":"Madhav R.","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-8966","authenticated-orcid":false,"given":"Sayeef","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6584-1578","authenticated-orcid":false,"given":"Erin","family":"Wilfong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2026.04.045_bib0001","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"10416","key":"10.1016\/j.jtct.2026.04.045_bib0002","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.045_bib0003","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0004","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","article-title":"Development and validation of a renal risk score in ANCA-associated glomerulonephritis","volume":"94","author":"Brix","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0005","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.045_bib0006","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/rheumatology\/kead491","article-title":"Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease","volume":"63","author":"Morrisroe","year":"2024","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.045_bib0007","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.045_bib0008","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/acn3.51492","article-title":"Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann Clin Translation Neurol"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.045_bib0009","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthrit Rheumatis"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0010","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40744-023-00595-5","article-title":"Association between mycophenolate mofetil use and subsequent infections among hospitalized patients with systemic lupus erythematosus: a nested case\u2013control study","volume":"10","author":"Guo","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jtct.2026.04.045_bib0011","article-title":"Mortality risk stratification using cluster analysis in patients with myositis-associated interstitial lung disease receiving initial triple-combination therapy","volume":"9","author":"Gono","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respirat J"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.045_bib0013","doi-asserted-by":"crossref","first-page":"1004.e1","DOI":"10.1016\/j.jtct.2025.09.015","article-title":"Validation of cure assumptions when analyzing ZUMA-7 follow-up data of axicabtagene ciloleucel and standard of care therapy in second-line relapsed\/refractory large B-cell lymphoma","volume":"31","author":"Perales","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.045_bib0014","first-page":"146","article-title":"Neonatal outcomes following 2 cases of maternal CAR-T therapy for high-grade B-cell lymphoma","volume":"122","author":"O'Reilly","year":"2025","journal-title":"Neonatology"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0015","first-page":"1119","article-title":"Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy","volume":"56","author":"Wang","year":"2024","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.045_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3899\/jrheum.191187","article-title":"Healthcare utilization and costs of systemic lupus erythematosus by disease Severity in the United States","volume":"48","author":"Murimi-Worstell","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jtct.2026.04.045_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","volume":"445","author":"Ting","year":"2023","journal-title":"J Neurolog Sci"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0018","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.045_bib0019","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"26","key":"10.1016\/j.jtct.2026.04.045_bib0020","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proceed Nat Acad Sci USA"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0021","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.045_bib0022","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.045_bib0023","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.045_bib0024","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann Rheumat Dis"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.045_bib0025","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Anna Rheumat Dis"},{"key":"10.1016\/j.jtct.2026.04.045_bib0026","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","author":"Lidar","year":"2024","journal-title":"Ann Rheumat Dis"},{"key":"10.1016\/j.jtct.2026.04.045_bib0027","article-title":"CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.04.045_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.045_bib0029","article-title":"IL23R-Specific CAR Tregs for the treatment of Crohn's disease","volume":"19","author":"Cui","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.045_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJMoa2509820","article-title":"CD19 CAR T-cell therapy for autoimmune hemolytic anemia","volume":"394","author":"Li","year":"2026","journal-title":"N Engl J Med"},{"issue":"10437","key":"10.1016\/j.jtct.2026.04.045_bib0031","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.045_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.045_bib0033","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T Cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.045_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100676","article-title":"CD19 CAR-T cell therapy in a pediatric patient with MDA5(+) dermatomyositis and rapidly progressive interstitial lung disease","volume":"6","author":"Par\u00eds-Mu\u00f1oz","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.045_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12969-024-00990-4","article-title":"CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?","volume":"22","author":"Stojkic","year":"2024","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jtct.2026.04.045_bib0036","article-title":"CAR T cells in pediatric systemic lupus erythematosus","author":"Simopoulou","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.045_bib0037","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent Bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-Cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2026.04.045_bib0038","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.045_bib0039","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.immuni.2021.02.018","article-title":"Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8(+) T cells during the primary immune response","volume":"54","author":"Levine","year":"2021","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.jtct.2026.04.045_bib0040","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.045_bib0041","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.2023019875","article-title":"Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT","volume":"142","author":"Senjo","year":"2023","journal-title":"Blood"},{"issue":"6753","key":"10.1016\/j.jtct.2026.04.045_bib0042","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science (New York, NY)"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.045_bib0043","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2010.07.009","article-title":"Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"17","author":"Loren","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.045_bib0044","doi-asserted-by":"crossref","first-page":"61","DOI":"10.46989\/001c.121404","article-title":"Allogeneic and other innovative chimeric antigen receptor platforms","volume":"6","author":"Jallouk","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"14","key":"10.1016\/j.jtct.2026.04.045_bib0045","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel\/ALLO-501 in Relapsed\/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2\/ALPHA Clinical Studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0046","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.045_bib0047","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.045_bib0048","unstructured":"(FACT) FftAoCT. FACT accreditation standards. (https:\/\/www.factglobal.org\/). Access date 4\/6\/2026"},{"key":"10.1016\/j.jtct.2026.04.045_bib0049","article-title":"Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience","author":"Ohuabunwa","year":"2025","journal-title":"Bone Marrow Transplantat"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0050","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41409-025-02551-z","article-title":"Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial","volume":"60","author":"Dholaria","year":"2025","journal-title":"Bone Marrow Transplantati"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.045_bib0051","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.045_bib0052","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-Cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtct.2026.04.045_bib0053","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.045_bib0054","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jtct.2024.05.010","article-title":"ACT To sustain: adoptive cell therapy to sustain access to non-commercialized genetically modified cell therapies","volume":"30","author":"Gardner","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.045_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13075-017-1501-z","article-title":"Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?","volume":"20","author":"Wahadat","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.045_bib0056","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00467-022-05670-7","article-title":"Recent advances in immunotherapies for lupus nephritis","volume":"38","author":"Kaneko","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jtct.2026.04.045_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.045_bib0058","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jtct.2026.04.045_bib0059","unstructured":"Clinicaltrials.gov. REACT-01: Reversing Autoimmunity Through Cell Therapy. National Library of Medicine Clinical Trials.Gov. ClinicalTrials.gov ID NCT06465147. (https:\/\/clinicaltrials.gov\/study\/NCT06465147)."},{"key":"10.1016\/j.jtct.2026.04.045_bib0060","unstructured":"Rheumatology ACo. Descartes-08: mRNA CAR T cell therapy receives FDA\u2019s rare pediatric designation to treat juvenile dermatomyositis. Published 01\/30\/2025. (https:\/\/www.the-rheumatologist.org\/article\/mrna-car-t-cell-therapy-receives-fdas-rare-pediatric-designation-to-treat-juvenile-dermatomyositis\/)."},{"key":"10.1016\/j.jtct.2026.04.045_bib0061","unstructured":"Clinicaltrials.gov. RESET-SSc: an open-label study to evaluate the safety and efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects With Systemic Sclerosis. NCT06328777. (https:\/\/www.clinicaltrials.gov\/search?term=CABA-201)."},{"key":"10.1016\/j.jtct.2026.04.045_bib0062","unstructured":"Clinicaltrials.gov. KYSA-6: a study of anti-CD19 chimeric antigen receptor T-Cell therapy, in patients with generalized myasthenia gravis. NCT06193889. Clinicaltrials.gov. (https:\/\/clinicaltrials.gov\/study\/NCT06193889?term=KYV-101&rank=1)."},{"issue":"1","key":"10.1016\/j.jtct.2026.04.045_bib0063","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-025-03564-1","article-title":"CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?","volume":"27","author":"Jouret","year":"2025","journal-title":"Arthritis Res Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:59:03Z","timestamp":1788551943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003313"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.045","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Disorders: An Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}